2023 American College of Rheumatology (ACR)/American College …
2024年7月8日 · Objective: We provide evidence-based recommendations regarding the treatment of interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases …
We provide evidence-based recommendations regarding screening for interstitial lung disease (ILD) and the monitoring for ILD progression in people with systemic autoimmune rheumatic …
For people with SSc-ILD and MCTD-ILD, we conditionally recommend tocilizumab as a first-line ILD treatment option. SARD-ILD, we conditionally recommend against leflunomide, …
2023 American College of Rheumatology (ACR)/American College …
2024年7月8日 · We provide evidence-based recommendations regarding the treatment of interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases …
2023 American College of Rheumatology (ACR)/American College …
2024年7月8日 · We provide evidence-based recommendations regarding screening for interstitial lung disease (ILD) and the monitoring for ILD progression in people with systemic autoimmune …
ILD screening and monitoring in patients with systemic autoimmune rheumatic disease (SARD) ACR, American College of Rheumatology; CHEST, American College of Chest Physicians; …
New ACR Guidelines for Screening, Monitoring, and Treatment of SARD-ILD ...
2023年12月1日 · For patients at an increased risk of ILD, the guideline conditionally recommends two tests for screening, including pulmonary function testing (PFT) with spirometry, lung …
The ACR and CHEST Release 2 New ILD Guidelines
2024年7月9日 · Working in conjunction with the American College of Chest Physicians, the ACR recently released two new guidelines on the screening, monitoring and treatment of patients …
Guiding ILD management in systemic autoimmune rheumatic
2024年9月4日 · Two guidelines endorsed by the ACR and the American College of Chest Physicians (ACCP) now provide evidence-based recommendations for the screening, …
Treatment of rheumatoid arthritis-associated interstitial lung …
2024年9月16日 · RA-ILD treatment decisions should consider articular activity, ILD activity, comorbidities, and potential for infection. We summarized the current treatment landscape for …